Company: BNBX
Filing Date: 2025-12-30
Form Type: 424B3
Source: 0001104659-25-125037
Chunk: 17

Company: BNB PLUS CORP.
Filing Date: 2025-12-30
Form: 424B3
Chunk 17
---

of its BNB-focused treasury strategy, on September 23, 2025, the Company entered into the Consulting Agreement with the Consultant
and an additional consulting agreement (collectively, the “Consulting Arrangements”) with the Consultant, pursuant to which
the Company (i) engaged the Consultant to provide certain advisory and marketing services and (ii) will receive premium sponsorship
benefits at all SALT conferences globally for a period of thirty-six months. The Consultant Arrangements have a term of three years
and shall terminate on September 23, 2028. Pursuant to the Consulting Arrangements, the Consultant shall be paid a fee of (a) $1,000,000
and (b) $250,000 paid quarterly from December 2025 until September 2027. In addition, immediately following the closing
of the Cash Private Placement, the Consultant received the Consultant Warrants exercisable for a number of shares of Common Stock equal
to 1% of the fully diluted outstanding equity of the Company as of immediately following the closing of the Cash Private Placement. The
exercise price per share of the Consultant Warrants is equal to 115% of the per-share purchase price under the Securities Purchase Agreements
and the Consultant Warrants have a term of five years from the date of issuance.

Formation of Build & Build, LLC

On October 19, 2025,
we formed Build & Build, LLC, a Delaware limited liability company and a 100% owned subsidiary of the Company (“Build &
Build”), in connection with our BNB Strategy. Pursuant to our BNB Strategy, Build & Build will be used to house certain
cryptocurrency assets of the Company.

Formation of BNBX Ltd.

On November 26, 2025,
we formed BNBX Ltd., a wholly owned subsidiary organized under the laws of the British Virgin Islands (B.V.I.) in connection with our
BNB Strategy. Pursuant to our BNB Strategy, BNBX Ltd. will be used to house certain cryptocurrency assets of the Company.

LineaRx Business Strategy

Through LineaRx, our 98%
owned subsidiary, we are developing and commercializing our LineaDNA and Linea IVT platforms for the manufacture of synthetic DNA and
associated enzymes for use in the production of nucleic acid-based therapeutics (the “Therapeutic DNA Production Services”).

Our nucleic-acid production
solutions enable the rapid and efficient cell-free manufacturing of high-quality DNA